scout
Opinion|Videos|August 29, 2024

Review of Data from EHA 2024 of Emerging Novel Bispecific Antibodies

Key opinion leaders provide concise insights on the potential of bispecific antibodies as emerging novel therapeutic agents for relapsed/refractory chronic lymphocytic leukemia.

Episodes in this series

Video content above is prompted by the following:

  • Briefly share perspective/insights on emerging novel agents in R/R CLL: Bispecific antibodies

Newsletter

Stay up to date on the most recent and practice-changing oncology data


Latest CME